BioMarin jumps as FDA expands PALYNZIQ label to PKU patients age 12+
BioMarin shares rose after an FDA decision expanded PALYNZIQ use to adolescents ages 12 and older with phenylketonuria. The label expansion opens a new treated population for a key enzyme-therapy franchise and adds a near-term commercial catalyst.
1. What’s moving the stock
BioMarin (BMRN) is trading higher as investors react to an FDA decision that expanded PALYNZIQ (pegvaliase-pqpz) to include adolescents ages 12 and older with phenylketonuria (PKU), adding a fresh growth driver for the company’s enzyme-therapy portfolio. The move comes as the market refocuses on BioMarin’s core commercial execution following its recent reset around ROCTAVIAN and ahead of additional 2026 catalysts.
2. Why it matters financially
PALYNZIQ is a commercial product within BioMarin’s enzyme-therapy franchise, and a pediatric/adolescent expansion can broaden the addressable market while leveraging an existing sales, patient-support, and distribution footprint. Investors typically view label expansions as higher-confidence growth versus earlier-stage pipeline events because they can convert more quickly into prescriptions and revenue, subject to payer coverage and patient onboarding timelines.
3. Context investors are weighing
In its February 23, 2026 update, BioMarin guided to 2026 total revenue of $3.325 billion to $3.425 billion (excluding any post-close contribution from the planned Amicus transaction), underscoring expectations for continued demand across enzyme therapies and VOXZOGO. The PALYNZIQ adolescent expansion is now part of the 2026 commercial narrative as investors look for incremental upside versus baseline guidance, as well as signals on launch cadence, reimbursement, and persistence in the younger population.